Is hippocampal atrophy a future drug target?

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1300-1306

  Dhikav, Vikas ^a   Anand, Kuljeet Singh ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 3BETA HYDROXYSTEROID DEHYDROGENASE ISOMERASE INHIBITOR; ADINAZOLAM; AGMATINE; CLOZAPINE; CYNOKETONE; DIZOCILPINE; DONEPEZIL; ESTROGEN; EXCITATORY AMINO ACID; FLUOXETINE; GLUCOCORTICOID; HALOPERIDOL; ISOMERASE INHIBITOR; LITHIUM; MIFEPRISTONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; QUETIAPINE; SEROTONIN; TACRINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

AGING; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BRAIN ATROPHY; DECLARATIVE MEMORY; DENDRITE; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; EPILEPSY; EPISODIC MEMORY; FOLLOW UP; HEAD INJURY; HIPPOCAMPUS; HUMAN; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SCHIZOPHRENIA; STRESS; SYMPTOM;

ATROPHY; DRUG DELIVERY SYSTEMS; FORECASTING; HIPPOCAMPUS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 33947706322     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.040     Document Type: Article

References (51)

1. Magarinos A.M., Deslandes A., and McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 371 2-3 (1999) 113-122
2. McEwen B.S., Conrad C.D., Kuroda Y., Frankfurt M., Magarinos A.M., and McKittrick C. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 371 2-3 (1999) 113-122
3. Reagan LP, Rosell DR, Wood GE, Spedding M, Munoz C, Rothstein J, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc Natl Acad Sci USA. 2004 17;101(7). p. 2179-84.
4. Wood G.E., Young L.T., Reagan L.P., Chen B., and McEwen B.S. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci USA 101 11 (2004) 3973-3978
5. McEwen B.S., and Olie J.P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychia 10 6 (2005) 525-537
6. McEwen B.S., Magarinos A.M., and Reagan L.P. Structural plasticity and tianeptine: cellular and molecular targets. Eur Psychia Suppl. 3 (2002) 318-330
7. Watanabe Y., Gould E., Daniels D.C., Cameron H., and McEwen B.S. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 222 1 (1992) 157-162
8. Conrad C.D., Galea L.A., Kuroda Y., and McEwen B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 110 6 (1996) 1321-1334
9. Reagan L.P., Rosell D.R., Wood G.E., Spedding M., Munoz C., Rothstein J., et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc Natl Acad Sci USA 101 7 (2004) 2179-2184 Epub 2004 Feb 6
10. Wagstaff A.J., Ormrod D., and Spencer C.M. Tianeptine: a review of its use in depressive disorders. CNS Drugs 15 3 (2001) 231-259
11. Reagan L.P., McKittrick C.R., and McEwen B.S. Corticosterone and phenytoin reduce neuronal nitric oxide synthase messenger RNA expression in rat hippocampus. Neurosci 91 1 (1999) 211-219
12. Bremner J.D., Mletzko T., Welter S., Quinn S., Williams C., Brummer M., et al. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. J Psychopharmacol 19 2 (2005) 159-165
13. Zhang Y.M., Yang Q., Xu C.T., Li K.S., and Li W.Q. Effects of phenytoin on morphology and structure of hippocampal CA3 pyramidal neurons of rats in chronic stress. Acta Pharmacol Sin 24 5 (2003) 403-407
14. Dhikav V. Can phenytoin prevent Alzheimer's disease?. Med Hypotheses 67 4 (2006) 725-728
15. Malberg J.E., Eisch A.J., Nestler E.J., and Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20 24 (2000) 9104-9110
16. Luo L., and Tan R.X. Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. Acta Pharmacol Sin 22 10 (2001) 865-870
17. Malberg J.E., and Duman R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacol 28 9 (2003) 1562-1571
18. de la Torre J.C., Pappas B.A., Prevot V., Emmerling M.R., Mantione K., Fortin T., et al. Hippocampal nitric oxide upregulation precedes memory loss and A beta 1-40 accumulation after chronic brain hypoperfusion in rats. Neurol Res 25 6 (2003) 635-641
19. Manev R., Uz T., and Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol 420 2-3 (2001) R1-R2
20. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003 8, 301(5634). p. 805-9.
21. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychia 63 2 (2006) 139-149
22. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., and Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75 4 (2000) 1729-1734
23. Kim J.S., Chang M.Y., Yu I.T., Kim J.H., Lee S.H., Lee Y.S., et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 89 2 (2004) 324-336
24. Son H., Yu I.T., Hwang S.J., Kim J.S., Lee S.H., Lee Y.S., et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 85 4 (2003) 872-881
25. Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25 18 (2005) 4493-4502
26. Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus.
27. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., and Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacol 29 6 (2004) 1063-1069
28. Wang H.D., Dunnavant F.D., Jarman T., and Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacol 29 7 (2004) 1230-1238
29. Dawirs R.R., Hildebrandt K., and Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm 105 2-3 (1998) 317-327
30. Malberg J.E., Eisch A.J., Nestler E.J., and Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20 24 (2000) 9104-9110
31. Warner-Schmidt J.L., and Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16 3 (2006) 239-249
32. Garcia R. Stress, metaplasticity, and antidepressants. Curr Mol Med 2 7 (2002) 629-638
33. Liu X.H., Wang P., and Barks J.D. The non-competitive AMPA antagonist LY 300168 (GYKI 53655) attenuates AMPA-induced hippocampal injury in neonatal rodents. Neurosci Lett 235 1-2 (1997) 93-97
34. Dragunow M., Faull R.L., and Jansen K.L. MK-801, an antagonist of NMDA receptors, inhibits injury-induced c-Fos protein accumulation in rat brain. Neurosci Lett 109 1-2 (1990) 128-133
35. Manji H.K., Moore G.J., and Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychia 48 8 (2000) 740-754
36. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24 29 (2004) 6590-6599
37. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 1053 (2005) 195-204
38. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychia 160 11 (2003) 2003-2011
39. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., and Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychia 162 4 (2005) 676-682
40. Riekkinen Jr. P., Soininen H., Helkala E.L., Partanen K., Laakso M., Vanhanen M., et al. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport 6 9 (1995) 1297-1300
41. Franklin T.B., and Perrot-Sinal T.S. Sex and ovarian steroids modulate brain-derived neurotrophic factor (BDNF) protein levels in rat hippocampus under stressful and non-stressful conditions. Psychoneuroendocrinol 31 1 (2006) 38-48
42. Fester L., Ribeiro-Gouveia V., Prange-Kiel J., von Schassen C., Bottner M., Jarry H., et al. Proliferation and apoptosis of hippocampal granule cells require local oestrogen synthesis. J Neurochem 97 4 (2006) 1136-1144
43. Eberling J.L., Wu C., Haan M.N., Mungas D., Buonocore M., and Jagust W.J. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol Aging 24 5 (2003) 725-732
44. Henderson V.W. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neurosci 138 3 (2006) 1031-1039
45. DeBattista C., and Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrin Met 17 3 (2006) 117-121
46. Pomara N., Greenberg W.M., Branford M.D., and Doraiswamy P.M. Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol Bull 37 2 (2003) 120-134
47. Belanoff J.K., Jurik J., Schatzberg L.D., DeBattista C., and Schatzberg A.F. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci 19 1-2 (2002) 201-206
48. Pomara N., Doraiswamy P.M., Tun H., and Ferris S. Mifepristone (RU-486) for Alzheimer's disease. Neurology 58 9 (2002) 1436
49. Wang W.P., Iyo A.H., Miguel-Hidalgo J., Regunathan S., and Zhu M.Y. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 1084 1 (2006) 210-216
50. Broderick P.A. Adinazolam affects biogenic amine release in hippocampal CA1 neuronal circuitry. Brain Res Bull 27 5 (1991) 689-692
51. Magarinos A.M., and McEwen B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69 1 (1995) 89-98